focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Good solid presentation. Will be much the same this evening no doubt.
I'm not sure what folk were expecting AS to say really. That Medusa19 will start selling the LFT at 8.30 am next Monday? That we've just got FDA approval for our LFT? That the AVA6000 clinical trial will be completed with good results by the end of July?
No price-sensitive information will ever be given in an investor webinar.
I was pleased to have the chance to top-up x2 during the presentation. Thank you MM, and impatient sellers!
https://attendee.gotowebinar.com/recording/2171214814960679183
The ABPI and Gov webinar which took place yesterday is now available to watch..
The title is "Update on the COVID-19 National Testing Programme".
Second US virus wave - cases over 2m
https://www.bloomberg.com/amp/news/articles/2020-06-10/second-u-s-virus-wave-emerges-after-state-reopenings?__twitter_impression=true
I know there is a filter to remove posts from individuals as you wish, but I would just love to have a filter that would hide posts from view that contained certain words - such as "Tom Winnifrith".
Just watched this. No mention of Avacta, but they will ne aware no doubt. I guess until there is an RNS saying the LFD is ready to launch "Avacta" cannot really be mentioned by name.
It's worth watching the webinar though if you want to learn more about the state of play of testing in the NHS - admittedly a smallish market in worldwide terms but good for AVCT PR if we were able to supply the LFD here.
The webinar and slides will be made available to watch - but I'm not sure where.
Does anybody here know?
This piece has just been included in Health Services Journal.
The first couple of paragraphs read :
"The NHS has been told to increase its covid-19 swab testing capacity again by at least double, HSJ has learned, including via efforts to expand rapid-turnaround tests.
Pathology chiefs across England have been asked to ensure each network of laboratories can process 3,000 PCR swab tests daily, although it is not clear on what timeline this is to be achieved.
HSJ also understands efforts to ramp up the number of PCR tests which can be turned around quickly — within an hour or four hours — are part of this objective, but are being hampered by a shortage of chemical reagents".
I won't post the whole article as the HSJ needs a subscription although they are providing COVID-19 articles free if you register for them.
See - https://www.hsj.co.uk
No Monkshead, they are not. At least not in the. NHS, whose labs I worked in for 35 years. Not an expert in MS though, far from it.
As you say MS machines can be expensive bits of kit, and a sound case of need based on clinical demand will have had to be made to get them purchased in the first place.
I assume the same sort of thing will hold in the rest of the world, where of course there are different ways of funding healthcare compared to our beloved NHS.
Having said all that, in the face of a pandemic no doubt work patterns and time would be modified to free up MS time for eg covid testing.
See 2nd RNS.
Avacta Group plc Investor Presentation
Alastair Smith, the Chief Executive Officer of Avacta Group plc discusses their recent, oversubscribed equity fundraising, use of funds and in more detail;
Key market opportunities relating to
COVID-19
Other diagnostic opportunities
Therapeutic pipeline
AVA004
Outlook
9 June 2020
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Investor Presentation
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Alastair Smith, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.
The event will be held on Thursday, 11 June 2020 at 2pm. Please register your interest at https://**********.brand.live/c/avacta-Investor-presentation.
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that a BAMS(TM) diagnostic test for the COVID-19 infection, being developed with its partner Adeptrix (Beverly MA, USA), has reached prototype stage and can detect the coronavirus spike protein in model samples in the concentration range appropriate for a clinical diagnostic test.